Return on Capital (ROC)
Return on capital (ROC) is after tax rate of return on net business assets. ROIC is unaffected by changes in interest rates or company debt and equity structure. It measures business productivity performance.
Return on Invested Capital (ROIC)
Celgene Corp., ROIC calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 4,676) | 1,913) | 1,954) | 1,787) | 1,826) | |
| Invested capital2 | 27,773) | 18,857) | 18,672) | 18,136) | 9,844) | |
| Performance Ratio | ||||||
| ROIC3 | 16.84% | 10.15% | 10.47% | 9.85% | 18.55% | |
| Benchmarks | ||||||
| ROIC, Competitors4 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 NOPAT. See details »
2 Invested capital. See details »
3 2018 Calculation
ROIC = 100 × NOPAT ÷ Invested capital
= 100 × 4,676 ÷ 27,773 = 16.84%
4 Click competitor name to see calculations.
| Performance ratio | Description | The company |
|---|---|---|
| ROIC | A measure of the periodic, after tax, cash-on-cash yield earned in the business. | Celgene Corp. ROIC deteriorated from 2016 to 2017 but then improved from 2017 to 2018 exceeding 2016 level. |
Decomposition of ROIC
Celgene Corp., decomposition of ROIC
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 Operating profit margin (OPM). See calculations »
2 Turnover of capital (TO). See calculations »
3 Effective cash tax rate (CTR). See calculations »
The primary reason for the increase in return on invested capital (ROIC) over 2018 year is the decrease in effective cash tax rate (CTR).
Operating Profit Margin (OPM)
Celgene Corp., OPM calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 4,676) | 1,913) | 1,954) | 1,787) | 1,826) | |
| Add: Cash operating taxes2 | 903) | 2,853) | 884) | 555) | 654) | |
| Net operating profit before taxes (NOPBT) | 5,579) | 4,766) | 2,839) | 2,342) | 2,480) | |
| Net product sales | 15,265) | 12,973) | 11,185) | 9,161) | 7,564) | |
| Add: Increase (decrease) in deferred revenue | 37) | 26) | (8) | 34) | 5) | |
| Adjusted net product sales | 15,302) | 12,999) | 11,177) | 9,195) | 7,569) | |
| Profitability Ratio | ||||||
| OPM3 | 36.46% | 36.66% | 25.40% | 25.47% | 32.76% | |
| Benchmarks | ||||||
| OPM, Competitors4 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2018 Calculation
OPM = 100 × NOPBT ÷ Adjusted net product sales
= 100 × 5,579 ÷ 15,302 = 36.46%
4 Click competitor name to see calculations.
| Profitability ratio | Description | The company |
|---|---|---|
| OPM | The operating profit margin (OPM) is the ratio of pretax economic earnings, or NOPBT, to sales. | Celgene Corp. OPM improved from 2016 to 2017 but then slightly deteriorated from 2017 to 2018. |
Turnover of Capital (TO)
Celgene Corp., TO calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net product sales | 15,265) | 12,973) | 11,185) | 9,161) | 7,564) | |
| Add: Increase (decrease) in deferred revenue | 37) | 26) | (8) | 34) | 5) | |
| Adjusted net product sales | 15,302) | 12,999) | 11,177) | 9,195) | 7,569) | |
| Invested capital1 | 27,773) | 18,857) | 18,672) | 18,136) | 9,844) | |
| Efficiency Ratio | ||||||
| TO2 | 0.55 | 0.69 | 0.60 | 0.51 | 0.77 | |
| Benchmarks | ||||||
| TO, Competitors3 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 Invested capital. See details »
2 2018 Calculation
TO = Adjusted net product sales ÷ Invested capital
= 15,302 ÷ 27,773 = 0.55
3 Click competitor name to see calculations.
| Efficiency ratio | Description | The company |
|---|---|---|
| TO | The turnover of capital (TO) is the ratio of sales to invested capital. Capital turnover is a function of the efficiency of working capital management and of net fixed assets. | Celgene Corp. TO improved from 2016 to 2017 but then deteriorated significantly from 2017 to 2018. |
Effective Cash Tax Rate (CTR)
Celgene Corp., CTR calculation, comparison to benchmarks
| Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Net operating profit after taxes (NOPAT)1 | 4,676) | 1,913) | 1,954) | 1,787) | 1,826) | |
| Add: Cash operating taxes2 | 903) | 2,853) | 884) | 555) | 654) | |
| Net operating profit before taxes (NOPBT) | 5,579) | 4,766) | 2,839) | 2,342) | 2,480) | |
| Tax Rate | ||||||
| CTR3 | 16.19% | 59.86% | 31.15% | 23.71% | 26.37% | |
| Benchmarks | ||||||
| CTR, Competitors4 | ||||||
| AbbVie Inc. | — | — | — | — | — | |
| Amgen Inc. | — | — | — | — | — | |
| Bristol-Myers Squibb Co. | — | — | — | — | — | |
| Eli Lilly & Co. | — | — | — | — | — | |
| Gilead Sciences Inc. | — | — | — | — | — | |
| Johnson & Johnson | — | — | — | — | — | |
| Merck & Co. Inc. | — | — | — | — | — | |
| Pfizer Inc. | — | — | — | — | — | |
| Regeneron Pharmaceuticals Inc. | — | — | — | — | — | |
| Thermo Fisher Scientific Inc. | — | — | — | — | — | |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31).
1 NOPAT. See details »
2 Cash operating taxes. See details »
3 2018 Calculation
CTR = 100 × Cash operating taxes ÷ NOPBT
= 100 × 903 ÷ 5,579 = 16.19%
4 Click competitor name to see calculations.
| Tax rate | Description | The company |
|---|---|---|
| CTR | Effective cash tax rate on operating income. | Celgene Corp. CTR increased from 2016 to 2017 but then decreased significantly from 2017 to 2018. |